Experts Raise Concerns Over UK’s Fast-Track Drug Approval System
14 May 2026

Experts Raise Concerns Over UK’s Fast-Track Drug Approval System

A newly introduced drug approval pathway in the United Kingdom is facing criticism from healthcare experts, who argue that the system may favor pharmaceutical companies more than patients or the public healthcare system. According to an analysis published in The BMJ, the accelerated process could lead to quicker market access for medicines without guaranteeing meaningful benefits for patients.

14 May 2026
Heart Attack Survivors May Face Faster Memory Decline, New Study Warns

People who have survived a heart attack could be at a greater risk of experiencing faster declines in memory and thinking abilities as they age, according to a new study published in the journal Stroke.

Researchers found that adults with a prior heart attack had a significantly higher likelihood of developing cognitive impairment over time compared to individuals without a history of heart attack. The findings highlight a growing connection between heart health and brain health, especially among older adults.

14 May 2026
FDA Approves BeOne’s BEQALZI for Blood Cancer
BeOne Medicines Ltd. a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to BEQALZI™ (bee-KAHL-zee; sonrotoclax), a foundational, next-generation BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma
14 May 2026
AstraZeneca’s Imfinzi Combination Shows Survival Benefit in Bladder Cancer Trial
High-level results from a planned interim analysis of the VOLGA Phase III trial showed perioperative treatment with Imfinzi (durvalumab) in combination with neoadjuvant enfortumab vedotin (EV) demonstrated statistically significant and clinically meaningful improvements in event-free survival (EFS) and overall survival (OS) in patients with muscle-invasive bladder cancer (MIBC) versus standard of care.
13 May 2026
23 Openings Pharma candidates under Ministry of Science & Technology, IIIM
M.Sc / M.Pharm in Pharmaceutical Chemistry, Analytical Chemistry, Chemistry, Pharmaceutical Analysis, or allied areas from a recognized University or equivalent. 
13 May 2026
Recruitment for Biochemistry, Chemistry, Pharma, Biotechnology candidates at IITR

The Indian Institute of Toxicology Research (IITR), established in 1965, a constituent laboratory of Council of Scientific & Industrial Research (CSIR) engaged in the Research & Development in the areas of Environmental Toxicology, Predictive Toxicology, Health Risk Assessment, Preventive Toxicology, Inhalation Toxicology, Analytical Toxicology, and also National S&T Missions. IITR has two campuses; the main campus is located at the centre of Lucknow City and the other campus at a distance of approx. 20 km from the main campus. 

13 May 2026
CDRI opens research opportunities for Pharma, Biotechnology, Life sciences candidates
M.Pharm / MS (Pharm). Experience in formulation development, pharmaceutical analysis and LC-MS, GPAT qualified
13 May 2026
Interview for Pharmacist at the office the of the District Health Society

Applications are invited from the eligible candidate for Walk-in-Interview for the post of Pharmacist (Homoeo) purely on contract basis on consolidated pay for the period of eleven months (11) under National Health Mission (NHM), South Andaman District to be held on 27.05.2026

Post : Pharmacist (Homoeo)

No of post : 01
Consolidated Pay per month : Rs. 21,632/-
Age Limit : Not below 18 year

13 May 2026
Pharmacists Openings at Homi Bhabha Cancer Hospital and Research Centre
Diploma in Pharmacy from a recognized institution and registered as pharmacist OR Bachelor Degree in Pharmacy (B.Pharm) from a recognized institution and registered as Pharmacist
13 May 2026
THSTI Offers Research Opportunities for Life Sciences or Pharmacy Candidates
Masters degree in any branch of life sciences or pharmacy or public health or health related discipline with minimum three years of relevant clinical trial monitoring experience.